Compare SHASUN PHARMA with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA PIRAMAL ENTERPRISES SHASUN PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 123.9 18.9 654.1% View Chart
P/BV x 8.5 1.2 709.1% View Chart
Dividend Yield % 0.2 1.5 15.8%  

Financials

 SHASUN PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-19
SHASUN PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs943,303 2.9%   
Low Rs461,797 2.5%   
Sales per share (Unadj.) Rs214.2716.5 29.9%  
Earnings per share (Unadj.) Rs5.379.7 6.7%  
Cash flow per share (Unadj.) Rs15.8107.9 14.7%  
Dividends per share (Unadj.) Rs1.0028.00 3.6%  
Dividend yield (eoy) %1.41.1 130.3%  
Book value per share (Unadj.) Rs53.31,477.5 3.6%  
Shares outstanding (eoy) m56.62184.45 30.7%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.33.6 9.2%   
Avg P/E ratio x13.132.0 40.9%  
P/CF ratio (eoy) x4.423.6 18.7%  
Price / Book Value ratio x1.31.7 75.9%  
Dividend payout %18.735.1 53.3%   
Avg Mkt Cap Rs m3,958470,292 0.8%   
No. of employees `000NA7.8 0.0%   
Total wages/salary Rs m2,16422,504 9.6%   
Avg. sales/employee Rs ThNM16,899.4-  
Avg. wages/employee Rs ThNM2,877.7-  
Avg. net profit/employee Rs ThNM1,879.9-  
INCOME DATA
Net Sales Rs m12,127132,153 9.2%  
Other income Rs m2293,128 7.3%   
Total revenues Rs m12,356135,281 9.1%   
Gross profit Rs m1,00966,290 1.5%  
Depreciation Rs m5945,202 11.4%   
Interest Rs m41544,097 0.9%   
Profit before tax Rs m23020,119 1.1%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-738,611 -0.8%   
Profit after tax Rs m30214,701 2.1%  
Gross profit margin %8.350.2 16.6%  
Effective tax rate %-31.742.8 -74.0%   
Net profit margin %2.511.1 22.4%  
BALANCE SHEET DATA
Current assets Rs m6,884122,742 5.6%   
Current liabilities Rs m8,456310,810 2.7%   
Net working cap to sales %-13.0-142.3 9.1%  
Current ratio x0.80.4 206.2%  
Inventory Days Days6223 267.2%  
Debtors Days Days10839 276.9%  
Net fixed assets Rs m4,970116,904 4.3%   
Share capital Rs m113369 30.7%   
"Free" reserves Rs m2,875272,161 1.1%   
Net worth Rs m3,020272,530 1.1%   
Long term debt Rs m1,817270,196 0.7%   
Total assets Rs m13,347856,261 1.6%  
Interest coverage x1.61.5 106.7%   
Debt to equity ratio x0.61.0 60.7%  
Sales to assets ratio x0.90.2 588.7%   
Return on assets %5.46.9 78.3%  
Return on equity %10.05.4 185.4%  
Return on capital %13.312.4 107.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84315,200 38.4%   
Fx outflow Rs m2,1734,889 44.5%   
Net fx Rs m3,66910,312 35.6%   
CASH FLOW
From Operations Rs m398-115,975 -0.3%  
From Investments Rs m-1,635-8,265 19.8%  
From Financial Activity Rs m1,309107,525 1.2%  
Net Cashflow Rs m71-16,650 -0.4%  

Share Holding

Indian Promoters % 39.2 52.9 74.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 4.0 90.0%  
FIIs % 17.6 26.6 66.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 16.5 240.0%  
Shareholders   20,750 93,274 22.2%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare SHASUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS